Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
Authors
Keywords
Immunoglobulin G, Immunoglobulin M, Infection, Multiple sclerosis, Ocrelizumab, Ofatumumab, Rituximab
Journal
Multiple Sclerosis and Related Disorders
Volume 52, Issue -, Pages 102988
Publisher
Elsevier BV
Online
2021-05-01
DOI
10.1016/j.msard.2021.102988
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
- (2021) Amber Salter et al. JAMA Neurology
- Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
- (2020) Khalaf Kridin et al. AUTOIMMUNITY REVIEWS
- Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019
- (2020) Adeel S. Zubair et al. JAMA Neurology
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
- (2020) Céline Louapre et al. JAMA Neurology
- Infections in patients diagnosed with multiple sclerosis: A multi-database study
- (2020) R. Persson et al. Multiple Sclerosis and Related Disorders
- Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
- (2020) Huah Shin Ng et al. Expert Opinion On Drug Safety
- Infections in patients with multiple sclerosis: A national cohort study in Sweden
- (2020) Anna Castelo-Branco et al. Multiple Sclerosis and Related Disorders
- Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
- (2020) Nora Möhn et al. Journal of Clinical Medicine
- Monoclonal Antibodies for Multiple Sclerosis: An Update
- (2019) Jonas Graf et al. BIODRUGS
- Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old
- (2019) Cecilia Trucchi et al. BMC HEALTH SERVICES RESEARCH
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study
- (2018) José Maria Andreas Wijnands et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety concerns and risk management of multiple sclerosis therapies
- (2016) P. Soelberg Sorensen ACTA NEUROLOGICA SCANDINAVICA
- Disease-modifying therapies and infectious risks in multiple sclerosis
- (2016) Alexander Winkelmann et al. Nature Reviews Neurology
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
- (2015) M Radaelli et al. Multiple Sclerosis Journal
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
- (2015) M Radaelli et al. Multiple Sclerosis Journal
- The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
- (2014) Helena Marco et al. BMC MUSCULOSKELETAL DISORDERS
- The Danish Microbiology Database (MiBa) 2010 to 2013
- (2014) M Voldstedlund et al. Eurosurveillance
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center
- (2012) Rodrigo Cartin-Ceba et al. ARTHRITIS AND RHEUMATISM
- Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
- (2012) Carla Casulo et al. Clinical Lymphoma Myeloma & Leukemia
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started